Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suziafu tablets
- Development stage
- Phase 3
- Lead developer
- Xinjiang Huakang Pharmaceutical
- Administration
- Oral
01
Overview
**Suziafu tablets** are an oral traditional Uyghur herbal medicine composed of *Artemisia* herb, lithospermum root, and wormwood. The product is intended to promote skin pigmentation and has been evaluated in randomized, double-blind, placebo-controlled Phase 3 studies for vitiligo, including non-segmental and stable disease, by Xinjiang Huakang Pharmaceutical. Its molecular pharmacology and specific biological targets have not been established. ([dayi.org.cn](https://www.dayi.org.cn/drug/1024040.html))
- Brand names
- KebailingXindaike Kebailing克白灵新代克白灵
- Other names
- Suzi Afu TabletsSuzi Afu PianSuzi'afu PianSuziafu苏孜阿甫片
Beyond the preview
Go deeper on suziafu tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suziafu tablets.